Open Tender Watch
Menu v
ACCESS EN PT
← Entities Public Body

Instituto Português de Oncologia do Porto Francisco Gentil, E. P. E.

NIF 506362299 · PT
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €24,040,998 2,490 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €24,040,998 2,490 contracts
A2 · Late Publication €1,035,917,975 65,510 contracts
Contract published to BASE more than 10 days after the signing date
LOW €1,035,917,975 65,510 contracts
A5 · Threshold Splitting €26,341,622 1,149 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €26,341,622 1,149 contracts
A9 · Price Overrun €145 1 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €145 1 contracts
A9 · Abnormal Price Reduction €425,514,289 9,019 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €425,514,289 9,019 contracts
B5 · Benford's Law Deviation €1,223,378,297 72,826 contracts
Entity's contract values deviate from the Benford leading-digit distribution (chi-square goodness-of-fit, min 20 contracts). Score: 35 (p<0.05) or 55 (p<0.01).
MEDIUM €1,223,378,297 72,826 contracts
C1 · Missing Supplier NIF €49,112,790 2,598 contracts
Supplier tax identifier absent or invalid, OR contract awarded (effective_price > 0) with no supplier identified. Score: 25 · Severity: Medium.
MEDIUM €49,112,790 2,598 contracts
C3 · Missing Mandatory Fields €22,786,424 1,959 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €22,786,424 1,959 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual
Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A9 · Price Overrun A9 · Abnormal Price Reduction B5 · Benford's Law Deviation C1 · Missing Supplier NIF C3 · Missing Mandatory Fields

Page 1 of 1457 · 72,826 results

1329/2025 - Convite à apresentação de propostas ao abrigo do(s) acordo(s)-quadro 2022/0014 (Medicamentos do aparelho digestivo), 2022/0019 (Medicamentos antipsicóticos, anestésicos e relaxantes musculares), 2022/0055 (Medicamentos diversos), 2022/0173 (Medicamentos diversos), 2023/0304 (Medicamentos do grupo 4: sangue), 2023/0305 (Medicamentos do aparelho cardiovascular), 2023/0436 (Medicamentos para o sistema nervoso central), 2023/0437 (Medicação antialérgica, vitaminas e sais minerais e medicamentos usados no tratamento de intoxicações), 2023/0481 (Medicamentos diversos), 2023/0490 (Medicamentos usados em afeções cutâneas), 2023/0491 (Medicamentos do foro oncológico e imunomoduladores), 2023/0492 (Medicamentos anti-infeciosos), 2023/0671 (Medicamentos diversos), 2024/0780 (Medicamentos do aparelho locomotor, usados no tratamento das doenças endócrinas e hormonas), 2024/0782 (Medicamentos usados em afeções oculares e otorrinolaringológicas), 2024/0898 (Medicamentos analgésicos, antip
PT · 11313325
A2 · Late Publication A9 · Abnormal Price Reduction +1
Ao abrigo de acor... €315,230,123 2025-02-19
Next →
Overview
Total Contracts
73,380
Score 2980825 · CRITICAL RISK
Digit Distribution
n = 72,826 contracts · χ² = 496.5326
1
30.8%
2
15.8%
3
11.8%
4
8.9%
5
8.2%
6
8.0%
7
6.4%
8
5.2%
9
5.0%
Observed Expected (Benford)